Auto-generated event page

Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)

Basel, February 27, 2026 – Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive ...

Score 41 low confidence 1 source posts Updated Feb 27, 2026, 11:41 AM UTC

Track This Event Open Event in App More Signal Pages

Cluster sources

Newest source rows first.

Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)

GlobeNewswire Public Companies • Feb 27, 2026, 11:29 AM UTC

Entity focus

Novartis CHMP

Direct link to post

https://pushme.site/signals/152682-novartis-receives-positive-chmp-opinion-for-remibrutinib-in-chronic-spon?utm_source=signal-152682&utm_medium=social&utm_campaign=signal-pages&utm_content=hero

Quick distribution loop

Step 1

Post this live link in threads where users ask how to monitor this event.

Step 2

Point readers to "Track This Event" for immediate conversion into an alert.

Step 3

Reuse entity keywords from this page for targeted follow-up replies.

Back to signal pages Open query hub